
Sign up to save your podcasts
Or


With Maurice Enriquez-Sarano, The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN & Marc Ferrini2, CH Saint Joseph and Saint Luc, Lyon, France.
In this podcast, Dr Maurice Enriquez-Sarano (The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, USA) joins Dr Marc Ferrini (Editor-in-Chief CardioPractice; CH Saint Joseph and Saint Luc, Lyon, France) to discuss our current understanding of mitral valve prolapse (MVP). The treatment of MVP has evolved in recent years, and we now know that a small fraction of myxomatous mitral valve prolapse patients may, over time, experience severe arrhythmia, irrespective of mitral regurgitation severity. Dr Sarano presents the current thinking on the diagnosis and the tools available for arrhythmic risk stratification.
By European Society of CardiologyWith Maurice Enriquez-Sarano, The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN & Marc Ferrini2, CH Saint Joseph and Saint Luc, Lyon, France.
In this podcast, Dr Maurice Enriquez-Sarano (The Allina Heart Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, USA) joins Dr Marc Ferrini (Editor-in-Chief CardioPractice; CH Saint Joseph and Saint Luc, Lyon, France) to discuss our current understanding of mitral valve prolapse (MVP). The treatment of MVP has evolved in recent years, and we now know that a small fraction of myxomatous mitral valve prolapse patients may, over time, experience severe arrhythmia, irrespective of mitral regurgitation severity. Dr Sarano presents the current thinking on the diagnosis and the tools available for arrhythmic risk stratification.

319 Listeners

504 Listeners

167 Listeners

40 Listeners

902 Listeners

31 Listeners

3,379 Listeners

56,978 Listeners

138 Listeners

65 Listeners

40 Listeners

18 Listeners

440 Listeners

34 Listeners

9 Listeners